| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6319913 | ENDO PHARMS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
| US6579865 | ENDO PHARMS | Penetration enhancing and irritation reducing systems |
Nov, 2018
(5 years ago) | |
Fortesta is owned by Endo Pharms.
Fortesta contains Testosterone.
Fortesta has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Fortesta are:
- US6319913
- US6579865
Fortesta was authorised for market use on 29 December, 2010.
Fortesta is available in gel, metered;transdermal dosage forms.
Fortesta can be used as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
The generics of Fortesta are possible to be released after 09 November, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 29, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 December, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL
FORTESTA family patents
